VivoSim Labs, Inc. - Common Stock (VIVS)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — May 17, 2026Investment Snapshot
- P/B of 0.76 — trading below book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -259.5%
- Revenue growing at 32% annually
VivoSim Labs, Inc. - Common Stock (VIVS) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $3 million . Key value metrics: P/B ratio 0.76, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
VivoSim Labs, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, VIVS shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -259.5% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.57.
StockPik's composite Value Score for VIVS is 50/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
VIVS reports a high gross margin of 98.3% (sector average: 40.1%) and a negative operating margin of -10,233.0%.
VIVS shows revenue growing at 32% year-over-year, with earnings growing at 83%.